{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T02:04:37Z","timestamp":1775268277195,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T00:00:00Z","timestamp":1541980800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Roche S.p.A."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s10067-018-4327-4","type":"journal-article","created":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T11:29:52Z","timestamp":1542022192000},"page":"841-849","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Subcutaneous tocilizumab alone or with a csDMARD in rheumatoid arthritis patients: subanalysis of Italian data from a multicenter phase IIIb\/IV trial"],"prefix":"10.1007","volume":"38","author":[{"given":"Laura","family":"Bazzichi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Nacci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Sinigaglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Bianchino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Caporali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,12]]},"reference":[{"key":"4327_CR1","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00296-014-2974-6","volume":"34","author":"M Rossini","year":"2014","unstructured":"Rossini M, Rossi E, Bernardi D, Viapiana O, Gatti D, Idolazzi L, Caimmi C, DeRosa M, Adami S (2014) Prevalence and incidence of rheumatoid arthritis in Italy. Rheumatol Int 34:659\u2013664","journal-title":"Rheumatol Int"},{"key":"4327_CR2","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jpsychores.2009.01.001","volume":"67","author":"M Kojima","year":"2009","unstructured":"Kojima M, Kojima T, Ishiguro N, Oguchi T, Oba M, Tsuchiya H, Sugiura F, Furukawa TA, Suzuki S, Tokudome S (2009) Psychosocial factors, disease status, and quality of life in patients with rheumatoid arthritis. J Psychosom Res 67:425\u2013431","journal-title":"J Psychosom Res"},{"key":"4327_CR3","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00296-015-3415-x","volume":"36","author":"PC Taylor","year":"2016","unstructured":"Taylor PC, Moore A, Vasilescu R, Alvir J, Tarallo M (2016) A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatol Int 36:685\u2013695","journal-title":"Rheumatol Int"},{"key":"4327_CR4","first-page":"49","volume":"7","author":"FS Luyster","year":"2011","unstructured":"Luyster FS, Chasens ER, Wasko MCM, Dunbar-Jacob J (2011) Sleep quality and functional disability in patients with rheumatoid arthritis. J Clin Sleep Med JCSM Off Publ Am Acad Sleep Med 7:49\u201355","journal-title":"J Clin Sleep Med JCSM Off Publ Am Acad Sleep Med"},{"key":"4327_CR5","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1007\/s10067-015-2875-4","volume":"34","author":"K L\u00f8ppenthin","year":"2015","unstructured":"L\u00f8ppenthin K, Esbensen BA, Jennum P, \u00d8stergaard M, Tolver A, Thomsen T, Midtgaard J (2015) Sleep quality and correlates of poor sleep in patients with rheumatoid arthritis. Clin Rheumatol 34:2029\u20132039","journal-title":"Clin Rheumatol"},{"key":"4327_CR6","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1002\/art.22033","volume":"54","author":"RN Maini","year":"2006","unstructured":"Maini RN, Taylor PC, Szechinski J, Pavelka K, Br\u00f6ll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J, Thomson D, Kishimoto T, CHARISMA Study Group (2006) Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54:2817\u20132829","journal-title":"Arthritis Rheum"},{"key":"4327_CR7","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","volume":"371","author":"JS Smolen","year":"2008","unstructured":"Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371:987\u2013997","journal-title":"Lancet"},{"key":"4327_CR8","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1002\/art.23940","volume":"58","author":"MC Genovese","year":"2008","unstructured":"Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, Woodworth T, Gomez-Reino JJ (2008) Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 58:2968\u20132980","journal-title":"Arthritis Rheum"},{"key":"4327_CR9","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1136\/ard.2008.092932","volume":"67","author":"P Emery","year":"2008","unstructured":"Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A et al (2008) IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67:1516\u20131523","journal-title":"Ann Rheum Dis"},{"key":"4327_CR10","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/ard.2008.105197","volume":"69","author":"G Jones","year":"2010","unstructured":"Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, Siri DA, Tomsic M, Alecock E, Woodworth T, Genovese MC (2010) Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 69:88\u201396","journal-title":"Ann Rheum Dis"},{"key":"4327_CR11","unstructured":"Anon. RoActemra, INN-tocilizumab - anx_135481_it.pdf. Available at: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2016\/20160729135481\/anx_135481_it.pdf . Accessed July 31, 2017"},{"key":"4327_CR12","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s10067-017-3587-8","volume":"36","author":"M Desplats","year":"2017","unstructured":"Desplats M, Pascart T, Jelin G, Norberciak L, Philippe P, Houvenagel E, Goeb V, Flipo RM (2017) Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study. Clin Rheumatol 36:1395\u20131400","journal-title":"Clin Rheumatol"},{"key":"4327_CR13","doi-asserted-by":"publisher","first-page":"443","DOI":"10.5414\/CP201819","volume":"51","author":"X Zhang","year":"2013","unstructured":"Zhang X, Georgy A, Rowell L (2013) Pharmacokinetics and pharmacodynamics of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, following single-dose administration by subcutaneous and intravenous routes to healthy subjects. Int J Clin Pharmacol Ther 51:443\u2013455","journal-title":"Int J Clin Pharmacol Ther"},{"key":"4327_CR14","doi-asserted-by":"publisher","first-page":"620","DOI":"10.5414\/CP201904","volume":"51","author":"X Zhang","year":"2013","unstructured":"Zhang X, Chen Y-C, Fettner S, Rowell L, Gott T, Grimsey P, Unsworth A (2013) Pharmacokinetics and pharmacodynamics of tocilizumab after subcutaneous administration in patients with rheumatoid arthritis. Int J Clin Pharmacol Ther 51:620\u2013630","journal-title":"Int J Clin Pharmacol Ther"},{"key":"4327_CR15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/jcph.185","volume":"54","author":"S Ohta","year":"2014","unstructured":"Ohta S, Tsuru T, Terao K, Mogi S, Suzaki M, Shono E, Ishida Y, Tarumi E, Imai M (2014) Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study). J Clin Pharmacol 54:109\u2013119","journal-title":"J Clin Pharmacol"},{"key":"4327_CR16","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/acr.22110","volume":"66","author":"A Ogata","year":"2014","unstructured":"Ogata A, Tanimura K, Sugimoto T, Inoue H, Urata Y, Matsubara T, Kondo M, Ueki Y, Iwahashi M, Tohma S, Ohta S, Saeki Y, Tanaka T, the Musashi Study Investigators (2014) Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res 66:344\u2013354","journal-title":"Arthritis Care Res"},{"key":"4327_CR17","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1002\/acr.22384","volume":"66","author":"A Kivitz","year":"2014","unstructured":"Kivitz A, Olech E, Borofsky M, Zazueta BM, Navarro-Sarabia F, Radominski SC, Merrill JT, Rowell L, Nasmyth-Miller C, Bao M, Wright S, Pope JE (2014) Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res 66:1653\u20131661","journal-title":"Arthritis Care Res"},{"key":"4327_CR18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1136\/annrheumdis-2013-203523","volume":"73","author":"GR Burmester","year":"2014","unstructured":"Burmester GR, Rubbert-Roth A, Cantagrel A, Hall S, Leszczynski P, Feldman D, Rangaraj MJ, Roane G, Ludivico C, Lu P, Rowell L, Bao M, Mysler EF (2014) A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis 73:69\u201374","journal-title":"Ann Rheum Dis"},{"key":"4327_CR19","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1136\/annrheumdis-2016-eular.1295","volume":"75","author":"E Choy","year":"2016","unstructured":"Choy E, Caporali R, Xavier R, Fautrel B, Sanmarti R, Bernasconi C et al (2016) FRI0215 subcutaneous tocilizumab as monotherapy or in combination with a csDMARDs in patients with rheumatoid arthritis\u2014interim analysis of a large phase IV international umbrella study, \u201cTozura.\u201d. Ann Rheum Dis 75:509\u2013510","journal-title":"Ann Rheum Dis"},{"key":"4327_CR20","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","volume":"28","author":"DJ Buysse","year":"1989","unstructured":"Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ (1989) The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28:193\u2013213","journal-title":"Psychiatry Res"},{"key":"4327_CR21","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315\u2013324","journal-title":"Arthritis Rheum"},{"key":"4327_CR22","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT (2010) Bingham CO, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69:1580\u20131588","journal-title":"Ann Rheum Dis"},{"key":"4327_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40744-014-0007-2","volume":"2","author":"AF Negoescu","year":"2015","unstructured":"Negoescu AF, \u00d6st\u00f6r AJK (2015) Refining the management of rheumatoid arthritis: the benefits of subcutaneous tocilizumab. Rheumatol Ther 2:17\u201331","journal-title":"Rheumatol Ther"},{"key":"4327_CR24","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s40744-016-0043-1","volume":"3","author":"A Kivitz","year":"2016","unstructured":"Kivitz A, Wallace T, Olech E, Borofsky M, Devenport J, Pei J, Michalska M (2016) Long-term safety and efficacy of subcutaneously administered tocilizumab for adult rheumatoid arthritis: a multicenter phase 3b long-term extension study. Rheumatol Ther 3:291\u2013304","journal-title":"Rheumatol Ther"},{"key":"4327_CR25","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1136\/annrheumdis-2015-207281","volume":"75","author":"GR Burmester","year":"2016","unstructured":"Burmester GR, Rubbert-Roth A, Cantagrel A, Hall S, Leszczynski P, Feldman D, Rangaraj MJ, Roane G, Ludivico C, Bao M, Rowell L, Davies C, Mysler EF (2016) Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA). Ann Rheum Dis 75:68\u201374","journal-title":"Ann Rheum Dis"},{"key":"4327_CR26","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1136\/annrheumdis-2016-210297","volume":"76","author":"GR Burmester","year":"2017","unstructured":"Burmester GR, Choy E, Kivitz A, Ogata A, Bao M, Nomura A, Lacey S, Pei J, Reiss W, Pethoe-Schramm A, Mallalieu NL, Wallace T, Michalska M, Birnboeck H, Stubenrauch K, Genovese MC (2017) Low immunogenicity of tocilizumab in patients with rheumatoid arthritis. Ann Rheum Dis 76:1078\u20131085","journal-title":"Ann Rheum Dis"},{"key":"4327_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/1759720X11431004","volume":"4","author":"F Striesow","year":"2012","unstructured":"Striesow F, Brandt A (2012) Preference, satisfaction and usability of subcutaneously administered methotrexate for rheumatoid arthritis or psoriatic arthritis: results of a postmarketing surveillance study with a high-concentration formulation. Ther Adv Musculoskelet Dis 4:3\u20139","journal-title":"Ther Adv Musculoskelet Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-018-4327-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4327-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4327-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T01:24:47Z","timestamp":1775265887000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-018-4327-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,12]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["4327"],"URL":"https:\/\/doi.org\/10.1007\/s10067-018-4327-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,12]]},"assertion":[{"value":"12 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by each institutional ethics committee\/review board, and all patients provided written informed consent. The study was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Laura Bazzichi received fees for consultation from Roche, AbbVie, BMS, Pfizer, and Merck (less than $10,000 per year, overall); Francesca Nacci has nothing to disclose; Luigi Sinigaglia has nothing to disclose; Laura Bianchino is a Roche employee; and Roberto Caporali received fees for consultation and speaker\u2019s activity from AbbVie, UCB, MSD, Italfarmaco, Roche, Pfizer, Lilly, and Novartis (less than $10,000 per year, overall).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}